• Je něco špatně v tomto záznamu ?

Confirmed disability progression as a marker of permanent disability in multiple sclerosis

S. Sharmin, F. Bovis, C. Malpas, D. Horakova, EK. Havrdova, G. Izquierdo, S. Eichau, M. Trojano, A. Prat, M. Girard, P. Duquette, M. Onofrj, A. Lugaresi, F. Grand'Maison, P. Grammond, P. Sola, D. Ferraro, M. Terzi, O. Gerlach, R. Alroughani, C....

. 2022 ; 29 (8) : 2321-2334. [pub] 20220609

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22025013

Grantová podpora
1129189 National Health and Medical Research Council
1140766 National Health and Medical Research Council
1157717 National Health and Medical Research Council

BACKGROUND AND PURPOSE: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained long-term disability worsening. METHODS: In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the development and 1481 in the validation cohort), a sustained progression score was calculated based on the demographic and clinical characteristics at the time of progression that were predictive of long-term disability worsening. The score was externally validated in the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) trial. RESULTS: The score was based on age, sex, MS phenotype, relapse activity, disability score and its change from baseline, number of affected functional system domains and worsening in six of the domains. In the internal validation cohort, a 61% lower chance of improvement was estimated with each unit increase in the score (hazard ratio 0.39, 95% confidence interval 0.29-0.52; discriminatory index 0.89). The proportions of progression events sustained at 5 years stratified by the score were 1: 72%; 2: 88%; 3: 94%; 4: 100%. The results of the CLARITY trial were confirmed for reduction of disability progression that was >88% likely to be sustained (events with score ˃1.5). CONCLUSIONS: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.

Austin Health Melbourne Vic Australia

Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino Avellino Italy

Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases Istanbul Turkey

Bombay Hospital Institute of Medical Sciences Mumbai India

Brain and Mind Centre Sydney NSW Australia

Central Clinical School Monash University Melbourne Vic Australia

Central Military Emergency University Hospital Titu Maiorescu University Bucharest Romania

CHUM and Universite de Montreal Montreal QC Canada

CISSS Chaudière Appalache Levis QC Canada

Cliniques Universitaires Saint Luc Brussels Belgium

CORe Department of Medicine University of Melbourne Melbourne Australia

Craigavon Area Hospital Craigavon UK

CSSS Saint Jerome Saint Jérôme QC Canada

Department of Basic Medical Sciences Neuroscience and Sense Organs University of Bari Bari Italy

Department of General Medicine Parma University Hospital Parma Italy

Department of Health Sciences University of Genoa Genoa Italy

Department of Medicine and Surgery University of Parma Parma Italy

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Czech Republic

Department of Neurology Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Neurology John Hunter Hospital Hunter New England Health Newcastle NSW Australia

Department of Neurology Razi Hospital Manouba Tunisia

Department of Neurology The Alfred Hospital Melbourne Vic Australia

Department of Neurology Zuyderland Medical Center Sittard Geleen The Netherlands

Department of Neuroscience Azienda Ospedaliera Universitaria Modena Italy

Department of Neuroscience Imaging and Clinical Sciences University G d'Annunzio Chieti Italy

Department of Rehabilitaiton ML Novarese Hospital Moncrivello Italy

Dipartimento di Scienze Biomediche e Neuromotorie Università di Bologna Bologna Italia

Division of Neurology Department of Medicine Amiri Hospital Sharq Kuwait

Dokuz Eylul University Konak Izmir Turkey

Flinders University Adelaide SA Australia

Geelong Hospital Geelong Vic Australia

Groene Hart Ziekenhuis Gouda The Netherlands

Haydarpasa Numune Training and Research Hospital Istanbul Turkey

Hopital Notre Dame Montreal QC Canada

Hospital de Galdakao Usansolo Galdakao Spain

Hospital General Universitario de Alicante Alicante Spain

Hospital Italiano Buenos Aires Argentina

Hospital Universitario de la Ribera Alzira Spain

Hospital Universitario Virgen Macarena Sevilla Spain

INEBA Institute of Neuroscience Buenos Aires Buenos Aires Argentina

Institute of Immunology and Infectious Diseases Murdoch University Perth WA Australia

Instituto de Investigación Sanitaria Biodonostia Department of Neurology Hospital Universitario Donostia San Sebastián Spain

IRCCS Istituto delle Scienze Neurologiche di Bologna Bologna Italia

IRCCS Mondino Foundation Pavia Italy

Isfahan University of Medical Sciences Isfahan Iran

Jahn Ferenc Teaching Hospital Budapest Hungary

Jewish General Hospital Montreal QC Canada

KTU Medical Faculty Farabi Hospital Trabzon Turkey

Liverpool Hospital Sydney NSW Australia

Medical Faculty 19 Mayis University Samsun Turkey

Melbourne MS Centre Department of Neurology Royal Melbourne Hospital Melbourne Australia

Monash Medical Centre Melbourne Vic Australia

Nehme and Therese Tohme Multiple Sclerosis Center American University of Beirut Medical Center Beirut Lebanon

Nemocnice Jihlava Jihlava Czech Republic

Neuro Rive Sud Greenfield Park QC Canada

Neurologic Clinic and Policlinic Departments of Medicine and Clinical Research University Hospital and University of Basel Basel Switzerland

Neurology Department King Fahad Specialist Hospital Dammam Dammam Saudi Arabia

Ospedali Riuniti di Salerno Salerno Italy

Perron Institute University of Western Australia Nedlands WA Australia

Rehabilitation and MS Centre Overpelt and Hasselt University Hasselt Belgium

Royal Brisbane and Women's Hospital Brisbane Qld Australia

Royal Hobart Hospital Hobart TAS Australia

School of Medicine and Public Health University Newcastle Newcastle NSW Australia

Semmelweis University Budapest Budapest Hungary

Sir Charles Gairdner Hospital Nedlands WA Australia

South East Trust Belfast UK

St Vincents Hospital Fitzroy Melbourne Vic Australia

Universidade Metropolitana de Santos Santos Brazil

Université Catholique de Louvain Louvain la Neuve Belgium

University hospital Aarhus Aarhus Denmark

University of Queensland Brisbane Qld Australia

UOC Neurologia Azienda Sanitaria Unica Regionale Marche AV3 Macerata Italy

Westmead Hospital Sydney NSW Australia

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025013
003      
CZ-PrNML
005      
20221031100212.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ene.15406 $2 doi
035    __
$a (PubMed)35582938
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sharmin, Sifat $u CORe, Department of Medicine, University of Melbourne, Melbourne, Australia
245    10
$a Confirmed disability progression as a marker of permanent disability in multiple sclerosis / $c S. Sharmin, F. Bovis, C. Malpas, D. Horakova, EK. Havrdova, G. Izquierdo, S. Eichau, M. Trojano, A. Prat, M. Girard, P. Duquette, M. Onofrj, A. Lugaresi, F. Grand'Maison, P. Grammond, P. Sola, D. Ferraro, M. Terzi, O. Gerlach, R. Alroughani, C. Boz, V. Shaygannejad, V. van Pesch, E. Cartechini, L. Kappos, J. Lechner-Scott, R. Bergamaschi, R. Turkoglu, C. Solaro, G. Iuliano, F. Granella, B. Van Wijmeersch, D. Spitaleri, M. Slee, P. McCombe, J. Prevost, R. Ampapa, S. Ozakbas, JL. Sanchez-Menoyo, A. Soysal, S. Vucic, T. Petersen, K. de Gans, E. Butler, S. Hodgkinson, Y. Sidhom, R. Gouider, E. Cristiano, T. Castillo-Triviño, ML. Saladino, M. Barnett, F. Moore, C. Rozsa, B. Yamout, O. Skibina, A. van der Walt, K. Buzzard, O. Gray, S. Hughes, AP. Sempere, B. Singhal, Y. Fragoso, C. Shaw, A. Kermode, B. Taylor, M. Simo, N. Shuey, T. Al-Harbi, R. Macdonell, JA. Dominguez, T. Csepany, CA. Sirbu, MP. Sormani, H. Butzkueven, T. Kalincik
520    9_
$a BACKGROUND AND PURPOSE: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained long-term disability worsening. METHODS: In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the development and 1481 in the validation cohort), a sustained progression score was calculated based on the demographic and clinical characteristics at the time of progression that were predictive of long-term disability worsening. The score was externally validated in the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) trial. RESULTS: The score was based on age, sex, MS phenotype, relapse activity, disability score and its change from baseline, number of affected functional system domains and worsening in six of the domains. In the internal validation cohort, a 61% lower chance of improvement was estimated with each unit increase in the score (hazard ratio 0.39, 95% confidence interval 0.29-0.52; discriminatory index 0.89). The proportions of progression events sustained at 5 years stratified by the score were 1: 72%; 2: 88%; 3: 94%; 4: 100%. The results of the CLARITY trial were confirmed for reduction of disability progression that was >88% likely to be sustained (events with score ˃1.5). CONCLUSIONS: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.
650    _2
$a kladribin $x terapeutické užití $7 D017338
650    _2
$a kohortové studie $7 D015331
650    12
$a posuzování pracovní neschopnosti $7 D004185
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a roztroušená skleróza $x farmakoterapie $x patologie $7 D009103
650    _2
$a relabující-remitující roztroušená skleróza $7 D020529
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bovis, Francesca $u Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
700    1_
$a Malpas, Charles $u CORe, Department of Medicine, University of Melbourne, Melbourne, Australia $u Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia
700    1_
$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Havrdova, Eva Kubala $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Izquierdo, Guillermo $u Hospital Universitario Virgen Macarena, Sevilla, Spain
700    1_
$a Eichau, Sara $u Hospital Universitario Virgen Macarena, Sevilla, Spain
700    1_
$a Trojano, Maria $u Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy
700    1_
$a Prat, Alexandre $u Hopital Notre Dame, Montreal, QC, Canada $u CHUM and Universite de Montreal, Montreal, QC, Canada
700    1_
$a Girard, Marc $u Hopital Notre Dame, Montreal, QC, Canada $u CHUM and Universite de Montreal, Montreal, QC, Canada
700    1_
$a Duquette, Pierre $u Hopital Notre Dame, Montreal, QC, Canada $u CHUM and Universite de Montreal, Montreal, QC, Canada
700    1_
$a Onofrj, Marco $u Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, Italy
700    1_
$a Lugaresi, Alessandra $u IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia $u Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italia
700    1_
$a Grand'Maison, Francois $u Neuro Rive-Sud, Greenfield Park, QC, Canada
700    1_
$a Grammond, Pierre $u CISSS Chaudière-Appalache, Levis, QC, Canada
700    1_
$a Sola, Patrizia $u Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy
700    1_
$a Ferraro, Diana $u Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy $1 https://orcid.org/https://orcid.org/0000000348183806
700    1_
$a Terzi, Murat $u Medical Faculty, 19 Mayis University, Samsun, Turkey $1 https://orcid.org/https://orcid.org/0000000235869115
700    1_
$a Gerlach, Oliver $u Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands
700    1_
$a Alroughani, Raed $u Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait
700    1_
$a Boz, Cavit $u KTU Medical Faculty Farabi Hospital, Trabzon, Turkey
700    1_
$a Shaygannejad, Vahid $u Isfahan University of Medical Sciences, Isfahan, Iran
700    1_
$a van Pesch, Vincent $u Cliniques Universitaires Saint-Luc, Brussels, Belgium $u Université Catholique de Louvain, Louvain-la-Neuve, Belgium $1 https://orcid.org/https://orcid.org/0000000328859004
700    1_
$a Cartechini, Elisabetta $u UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, Italy
700    1_
$a Kappos, Ludwig $u Neurologic Clinic and Policlinic, Departments of Medicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland
700    1_
$a Lechner-Scott, Jeannette $u School of Medicine and Public Health, University Newcastle, Newcastle, NSW, Australia $u Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia
700    1_
$a Bergamaschi, Roberto $u IRCCS Mondino Foundation, Pavia, Italy
700    1_
$a Turkoglu, Recai $u Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
700    1_
$a Solaro, Claudio $u Department of Rehabilitaiton, ML Novarese Hospital, Moncrivello, Italy $1 https://orcid.org/https://orcid.org/0000000267134623
700    1_
$a Iuliano, Gerardo $u Ospedali Riuniti di Salerno, Salerno, Italy
700    1_
$a Granella, Franco $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Department of General Medicine, Parma University Hospital, Parma, Italy
700    1_
$a Van Wijmeersch, Bart $u Rehabilitation and MS-Centre Overpelt and Hasselt University, Hasselt, Belgium
700    1_
$a Spitaleri, Daniele $u Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy
700    1_
$a Slee, Mark $u Flinders University, Adelaide, SA, Australia
700    1_
$a McCombe, Pamela $u University of Queensland, Brisbane, Qld, Australia $u Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia
700    1_
$a Prevost, Julie $u CSSS Saint-Jerome, Saint-Jérôme, QC, Canada
700    1_
$a Ampapa, Radek $u Nemocnice Jihlava, Jihlava, Czech Republic
700    1_
$a Ozakbas, Serkan $u Dokuz Eylul University, Konak/Izmir, Turkey
700    1_
$a Sanchez-Menoyo, Jose Luis $u Hospital de Galdakao-Usansolo, Galdakao, Spain $1 https://orcid.org/https://orcid.org/0000000326348294
700    1_
$a Soysal, Aysun $u Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey
700    1_
$a Vucic, Steve $u Westmead Hospital, Sydney, NSW, Australia $1 https://orcid.org/https://orcid.org/0000000209564633
700    1_
$a Petersen, Thor $u University hospital Aarhus, Aarhus, Denmark
700    1_
$a de Gans, Koen $u Groene Hart Ziekenhuis, Gouda, The Netherlands
700    1_
$a Butler, Ernest $u Monash Medical Centre, Melbourne, Vic., Australia
700    1_
$a Hodgkinson, Suzanne $u Liverpool Hospital, Sydney, NSW, Australia
700    1_
$a Sidhom, Youssef $u Department of Neurology, Razi Hospital, Manouba, Tunisia
700    1_
$a Gouider, Riadh $u Department of Neurology, Razi Hospital, Manouba, Tunisia $1 https://orcid.org/https://orcid.org/0000000196153797
700    1_
$a Cristiano, Edgardo $u Hospital Italiano, Buenos Aires, Argentina
700    1_
$a Castillo-Triviño, Tamara $u Instituto de Investigación Sanitaria Biodonostia, Department of Neurology, Hospital Universitario Donostia, San Sebastián, Spain
700    1_
$a Saladino, Maria Laura $u INEBA - Institute of Neuroscience Buenos Aires, Buenos Aires, Argentina
700    1_
$a Barnett, Michael $u Brain and Mind Centre, Sydney, NSW, Australia
700    1_
$a Moore, Fraser $u Jewish General Hospital, Montreal, QC, Canada
700    1_
$a Rozsa, Csilla $u Jahn Ferenc Teaching Hospital, Budapest, Hungary $1 https://orcid.org/https://orcid.org/0000000194156177
700    1_
$a Yamout, Bassem $u Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon $1 https://orcid.org/https://orcid.org/0000000225406651
700    1_
$a Skibina, Olga $u Central Clinical School, Monash University, Melbourne, Vic., Australia $u Department of Neurology, The Alfred Hospital, Melbourne, Vic., Australia
700    1_
$a van der Walt, Anneke $u Central Clinical School, Monash University, Melbourne, Vic., Australia $u Department of Neurology, The Alfred Hospital, Melbourne, Vic., Australia
700    1_
$a Buzzard, Katherine $u Central Clinical School, Monash University, Melbourne, Vic., Australia $u Department of Neurology, The Alfred Hospital, Melbourne, Vic., Australia
700    1_
$a Gray, Orla $u South East Trust, Belfast, UK
700    1_
$a Hughes, Stella $u Craigavon Area Hospital, Craigavon, UK
700    1_
$a Sempere, Angel Perez $u Hospital General Universitario de Alicante, Alicante, Spain
700    1_
$a Singhal, Bhim $u Bombay Hospital Institute of Medical Sciences, Mumbai, India
700    1_
$a Fragoso, Yara $u Universidade Metropolitana de Santos, Santos, Brazil $1 https://orcid.org/https://orcid.org/000000018726089X
700    1_
$a Shaw, Cameron $u Geelong Hospital, Geelong, Vic., Australia
700    1_
$a Kermode, Allan $u Perron Institute, University of Western Australia, Nedlands, WA, Australia $u Institute of Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia $u Sir Charles Gairdner Hospital, Nedlands, WA, Australia
700    1_
$a Taylor, Bruce $u Royal Hobart Hospital, Hobart, TAS, Australia
700    1_
$a Simo, Magdolna $u Semmelweis University Budapest, Budapest, Hungary
700    1_
$a Shuey, Neil $u St Vincents Hospital, Fitzroy, Melbourne, Vic., Australia
700    1_
$a Al-Harbi, Talal $u Neurology Department, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia
700    1_
$a Macdonell, Richard $u Austin Health, Melbourne, Vic., Australia
700    1_
$a Dominguez, Jose Andres $u Hospital Universitario de la Ribera, Alzira, Spain
700    1_
$a Csepany, Tunde $u Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
700    1_
$a Sirbu, Carmen Adella $u Central Military Emergency University Hospital, Titu Maiorescu University, Bucharest, Romania
700    1_
$a Sormani, Maria Pia $u Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
700    1_
$a Butzkueven, Helmut $u Central Clinical School, Monash University, Melbourne, Vic., Australia $u Department of Neurology, The Alfred Hospital, Melbourne, Vic., Australia
700    1_
$a Kalincik, Tomas $u CORe, Department of Medicine, University of Melbourne, Melbourne, Australia $u Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia $1 https://orcid.org/https://orcid.org/0000000337781376
773    0_
$w MED00001629 $t European journal of neurology $x 1468-1331 $g Roč. 29, č. 8 (2022), s. 2321-2334
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35582938 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100210 $b ABA008
999    __
$a ok $b bmc $g 1854623 $s 1176303
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 29 $c 8 $d 2321-2334 $e 20220609 $i 1468-1331 $m European journal of neurology $n Eur J Neurol $x MED00001629
GRA    __
$a 1129189 $p National Health and Medical Research Council
GRA    __
$a 1140766 $p National Health and Medical Research Council
GRA    __
$a 1157717 $p National Health and Medical Research Council
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace